[
  {
    "ts": null,
    "headline": "Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts",
    "summary": "On Wednesday, Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over year on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion. Needham analyst Ami Fadia expects challenges in the multiple sclerosis segment, as growth from key product launches isn’t enough to make up for declines. While Leqembi sales performed well outside the U.S. and Skyclarys",
    "url": "https://finnhub.io/api/news?id=dae94e7680e4772a283464df31e705d1e54ccce27715cb88eccc465530f3ffbd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739475019,
      "headline": "Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts",
      "id": 133191265,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "On Wednesday, Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over year on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion. Needham analyst Ami Fadia expects challenges in the multiple sclerosis segment, as growth from key product launches isn’t enough to make up for declines. While Leqembi sales performed well outside the U.S. and Skyclarys",
      "url": "https://finnhub.io/api/news?id=dae94e7680e4772a283464df31e705d1e54ccce27715cb88eccc465530f3ffbd"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Still Offering Value, RBC Says",
    "summary": "Biogen (BIIB) showed how it has \"successfully\" reprioritized R&D and rightsized operating expenses i",
    "url": "https://finnhub.io/api/news?id=ac7421229e0dd505d9f695adba0cabbe389c32a3445a8781c522bc1490bed4ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739471463,
      "headline": "Biogen Still Offering Value, RBC Says",
      "id": 133191266,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) showed how it has \"successfully\" reprioritized R&D and rightsized operating expenses i",
      "url": "https://finnhub.io/api/news?id=ac7421229e0dd505d9f695adba0cabbe389c32a3445a8781c522bc1490bed4ee"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
    "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=392e07e97c6aff751bc0ef398717d8c5b39a206579b0395278404763d8e9d32b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739466420,
      "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
      "id": 132734254,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=392e07e97c6aff751bc0ef398717d8c5b39a206579b0395278404763d8e9d32b"
    }
  }
]